CN114983879A - 一种厚朴酚漱口水及其制备方法 - Google Patents
一种厚朴酚漱口水及其制备方法 Download PDFInfo
- Publication number
- CN114983879A CN114983879A CN202210862023.8A CN202210862023A CN114983879A CN 114983879 A CN114983879 A CN 114983879A CN 202210862023 A CN202210862023 A CN 202210862023A CN 114983879 A CN114983879 A CN 114983879A
- Authority
- CN
- China
- Prior art keywords
- magnolol
- mouthwash
- water
- peppermint
- glucan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 title claims abstract description 167
- 239000002324 mouth wash Substances 0.000 title claims abstract description 79
- 229940051866 mouthwash Drugs 0.000 title claims abstract description 69
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 66
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 51
- 244000246386 Mentha pulegium Species 0.000 claims abstract description 26
- 235000016257 Mentha pulegium Nutrition 0.000 claims abstract description 26
- 235000004357 Mentha x piperita Nutrition 0.000 claims abstract description 26
- 235000001050 hortel pimenta Nutrition 0.000 claims abstract description 26
- 239000000463 material Substances 0.000 claims abstract description 19
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims description 46
- 235000011187 glycerol Nutrition 0.000 claims description 25
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 20
- 229920002498 Beta-glucan Polymers 0.000 claims description 20
- 230000008569 process Effects 0.000 claims description 20
- 238000001914 filtration Methods 0.000 claims description 10
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 9
- 235000019477 peppermint oil Nutrition 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 238000011049 filling Methods 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 238000009210 therapy by ultrasound Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 12
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 8
- 241000894006 Bacteria Species 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 241001673966 Magnolia officinalis Species 0.000 description 9
- 241000194019 Streptococcus mutans Species 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000011835 investigation Methods 0.000 description 6
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- 230000000675 anti-caries Effects 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 208000002925 dental caries Diseases 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 239000004570 mortar (masonry) Substances 0.000 description 3
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000001013 cariogenic effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N methyl cyanide Natural products CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 241000186045 Actinomyces naeslundii Species 0.000 description 1
- 241000186044 Actinomyces viscosus Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000662429 Fenerbahce Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 102000000340 Glucosyltransferases Human genes 0.000 description 1
- 108010055629 Glucosyltransferases Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 235000001878 Mentha haplocalyx Nutrition 0.000 description 1
- 244000280293 Mentha haplocalyx Species 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241000194023 Streptococcus sanguinis Species 0.000 description 1
- 241000193987 Streptococcus sobrinus Species 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000006136 alcoholysis reaction Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- -1 diphenol compound Chemical class 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000001648 gingival epithelial cell Anatomy 0.000 description 1
- 101150110739 gtfD gene Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000013173 literature analysis Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cosmetics (AREA)
Abstract
本发明提供了一种厚朴酚漱口水,每100mL漱口水包括如下原辅料制成:厚朴酚5mg,聚乙二醇400 10~20mL,甘油5~20mL,薄荷水20~40mL,余量为水。本发明以厚朴酚为主要成分制备的抑菌漱口水具有抑菌、抗龋齿等功效;口感好,气味宜人,用于日常的口腔护理,使用方便,成分安全,无毒副作用,误食无安全隐患。且本发明漱口水性状稳定,成分简单,制备过程工艺简单,周期短,易于生产,应用前景广阔。
Description
技术领域
本发明属于日用化学品领域,具体涉及一种厚朴酚漱口水及其制备方法。
背景技术
随着社会生活水平的提升,人们越来越注重社会生活礼仪,口腔问题作为社会生活礼仪中的关键问题之一受到了人们极大的关注。漱口水作为口腔清洁的必备产品之一,被广泛地应用于龋齿的护理和防治等多个方面。漱口水一般可以解决多种的口腔问题,具有消炎、杀菌、清新口气等多种功能。
目前国内市场上漱口水的种类较多,但是大多数漱口水的抗龋齿效果有限。为了提高抗龋齿效果,许多漱口水会加入抗生素类物质或者氟化物等,但这些物质对口腔刺激性较大,误食可能会导致不良反应,尤其对于婴幼儿使用者,存在较大的安全隐患。目前较为缺少安全、有效的抗龋齿漱口水制剂,亟需开发安全、有效、可长期使用的抗龋齿漱口水。
厚朴酚是厚朴中的一种联苯二酚化合物,是其主要的药效成分之一。厚朴是由木兰科植物厚朴Magnolia officinalis Rehd.et Wils.和凹叶厚朴Magnolia officinalisRehd.et Wils.var.biloba Rehd.et Wils.的干燥干皮、根皮和枝皮。日本学者Namba等对180种生药进行筛选发现,厚朴的乙醚和加醇提取物对变形链球菌有很强的抗菌作用,厚朴已成为防治龋齿的最有效的天然药物之一。厚朴酚为天然药物厚朴抗龋齿的最主要的药效成分,有学者通过建立体外菌斑模型,研究发现用不同浓度的厚朴酚处理唾液包被的羟基磷灰石表面后,变形链球菌的粘附量明显减少。Huang BB等学者的研究发现厚朴酚能较强的抑制变形链球菌葡糖基转移酶活性,使得葡聚糖合成量减少,从而减缓变形链球菌产酸引起的牙体硬组织破坏。Sakaue Y等学者通过建立变形链球菌生物膜体外模型,研究发现厚朴酚作用于变形链球菌生物膜后可使膜内活菌比例明显下降,并能明显抑制变形链球菌生物膜的致龋毒力因子ffh、gtfD、pdp的转录表达,降低变形链球菌的致龋性。厚朴酚(50μg/mL)对牙龈上皮细胞系Ca9-22没有无细胞毒性。厚朴酚(10mg/mL)对大肠杆菌的生长没有抑制作用,不会影响肠道正常菌群。由此可见,厚朴酚抗龋齿的作用明确,对口腔和肠道安全无毒副作用。此外,厚朴酚还具有抗炎和抗氧化等作用。
然而,厚朴酚溶解度差,作为漱口水有效成分,如何既保证有效厚朴酚浓度,又改良气味、口感和性状,提升大众接受度,成为一大难题。
发明内容
本发明的目的在于提供一种厚朴酚漱口水及其制备方法。
本发明提供了一种厚朴酚漱口水,每100mL漱口水包括如下原辅料制成:
厚朴酚5mg,聚乙二醇400 10~20mL,甘油5~20mL,薄荷水10~40mL。
进一步地,每100mL漱口水包括如下原辅料制成:
厚朴酚5mg,聚乙二醇400 20mL,甘油10~20mL,薄荷水10~20mL;
优选为:厚朴酚5mg,聚乙二醇400 20mL,甘油20mL,薄荷水20mL。
更进一步地,上述薄荷水是薄荷油的饱和水溶液,所述甘油是天然甘油。
更进一步地,上述漱口水还包括β-葡聚糖。
更进一步地,每100mL漱口水中所述β-葡聚糖的用量不超过10mg;优选的,所述β-葡聚糖的用量为5mg。
更进一步地,每100mL漱口水由如下原辅料制成:
厚朴酚5mg,液态聚乙二醇20mL,甘油10~20mL,薄荷水10~20mL,β-葡聚糖5~10mg,余量为水;
优选为:厚朴酚5mg,聚乙二醇400 20mL,甘油20mL,薄荷水20mL,β-葡聚糖5mg,余量为水。
更进一步地,上述的厚朴酚漱口水是将所述原辅料混匀后超声,静置,过滤,灭菌制得。
进一步地,上述制备方法包括如下步骤:
(1)称取厚朴酚,依次加入除水以外的辅料,每次加入辅料后均混匀,最后加水定容;
(2)超声,静置,过滤。
更进一步地,步骤(2)所述超声时间为10~20min,所述静置时间为2~4h;优选地,所述超声时间为15min,所述静置时间为3h。
更进一步地,上述制备方法还包括灌装、灭菌步骤。
本发明的有益效果:本发明以厚朴酚为主要成分制备的抑菌漱口水,对变形链球菌、远缘链球菌、血链球菌、内氏放线菌、粘性放线菌、乳酸杆菌的抑菌率较高,抗龋齿效果佳。本发明厚朴酚漱口水口感好,可保持口气清新,并伴有淡淡的怡人清香。用于日常的口腔护理,使用方便,成分安全,无毒副作用,误食无安全隐患。漱口水性状稳定,成分简单,制备过程工艺简单,周期短,易于生产,市场竞争力强,应用前景广阔。
本发明术语解释:
“薄荷油”:即薄荷素油,为唇形科植物薄荷Mentha haplocalyx Briq.的新鲜茎和叶经水蒸气蒸馏、冷冻、部分脱脑加工提取的挥发油。
“天然甘油”:以棕榈油、大豆油等天然油脂为原料,通过水解、皂化或醇解制备得到的甘油。
“聚乙二醇400”:平均数均分子量为400g/mol的聚乙二醇。
显然,根据本发明的上述内容,按照本领域的普通技术知识和惯用手段,在不脱离本发明上述基本技术思想前提下,还可以做出其它多种形式的修改、替换或变更。
以下通过实施例形式的具体实施方式,对本发明的上述内容再作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下的实例。凡基于本发明上述内容所实现的技术均属于本发明的范围。
具体实施方式
本发明所用原料与设备均为已知产品,通过购买市售产品所得。
本发明实施例所用厚朴酚,CAS号:528-43-8,Adamas试剂品牌生产,纯度98%+。
本发明实施例所用薄荷水是薄荷油的饱和水溶液(约0.05%,mL/mL)。可参照《中药药剂实验》第五章-溶液型液体药剂的制备所公开的方法制备,例如,可以按照如下方式制备:
1)称取滑石粉1.5g,置于干燥研钵中,将薄荷油0.2ml加到滑石粉上,充分研匀。
2)量取蒸馏水95ml,分次加到研钵中,先加少量,研匀后再逐渐加入其余的蒸馏水,每次都要研匀,最后留下少量蒸馏水。
3)上述混合液移入150ml的具塞玻璃瓶中,用余下的蒸馏水将研钵中的滑石粉冲洗入玻璃瓶,加塞剧烈振10min。用润湿过的滤纸反复过滤,直至澄清。再从滤器上添加蒸馏水至100ml,即得。
制备时的用量为溶解量的4倍,配制时并不能完全溶解。得到的为薄荷油的饱和水溶液(约0.05%,mL/mL)。
上述制备方法不构成对薄荷油的饱和水溶液的限制,通过其他方式制备得到的薄荷油饱和水溶液(薄荷水)同样适用于本发明漱口水的制备。
实施例1、本发明厚朴酚漱口水的制备
制备方法:称取厚朴酚5mg,定量,依次加入PEG-400 20mL、部分纯水、甘油20mL、β-葡聚糖5mg及薄荷水20mL,每加入一种辅料均充分混匀后再加下一种辅料,最后用纯水定容至100mL,超声15min,放置3h,过滤,灌装、灭菌、贴标签,即得新型厚朴酚漱口水。
实施例2、本发明厚朴酚漱口水的制备
制备方法:称取厚朴酚5mg,定量,依次加入PEG-400 10mL、部分纯水、甘油20mL、薄荷水20mL,每加入一种辅料均充分混匀后再加下一种辅料,最后用纯水定容至100mL,超声15min,放置3h,过滤,灌装、灭菌、贴标签,即得新型厚朴酚漱口水。
实施例3、本发明厚朴酚漱口水的制备
制备方法:称取厚朴酚5mg,定量,依次加入PEG-400 20mL、部分纯水、甘油5mL、β-葡聚糖10mg及薄荷水20mL,每加入一种辅料均充分混匀后再加下一种辅料,最后用纯水定容至100mL,超声15min,放置3h,过滤,灌装、灭菌、贴标签,即得新型厚朴酚漱口水。
实施例4、本发明厚朴酚漱口水的制备
制备方法:称取厚朴酚5mg,定量,依次加入PEG-400 20mL、部分纯水、甘油10mL、薄荷水40mL,每加入一种辅料均充分混匀后再加下一种辅料,最后用纯水定容至100mL,超声15min,放置3h,过滤,灌装、灭菌、贴标签,即得新型厚朴酚漱口水。
以下通过实验例证明本发明的有益效果。
实验例1、本发明漱口水制备工艺考察
1、实验方法
1.1工艺考察设计
通过文献及预试验对漱口水的辅料及辅料的添加量进行筛选,确立了以PEG400添加量(A)、甘油添加量(B)、β-葡聚糖添加量(C)、薄荷水添加量(D)的4因素3水平L9(34)正交试验,正交因素水平见表1。
表1正交因素表
1.2工艺考察指标
根据文献调研,漱口水成型工艺研究多以漱口水感官评价为考察指标。同时,本实验研究考虑到厚朴酚为主要抗龋齿有效成分及其难溶性,加入漱口水中厚朴酚的浓度为量化指标。因此,本实验以漱口水感官评价和厚朴酚的含量指标作为本实验漱口水的工艺考察指标。
1.2.1漱口水感官评价表
表2漱口水感官评价表
1.2.2厚朴酚含量测定HPLC方法
(1)色谱条件
色谱柱:色谱柱AcclaimTM 120 C18(5μm,4.6mm×250mm)
流动相:甲醇:水:乙腈(50:20:30)
检测波长:294nm
流速:1ml/min
柱温:25℃
(2)对照品溶液的制备
取厚朴酚对照品1.00mg,精密称定,置于2ml容量瓶中,用纯甲醇溶液定容,摇匀,制成浓度为0.5mg/ml的对照品溶液。
(3)样品的制备
取10ml漱口水置于离心管中,离心15min,取上清液1ml,精密量取,加入5ml容量瓶,加纯甲醇定容至刻度线,混匀,过0.22um微孔滤膜,即得。
(4)按照峰面积归一法计算漱口水中厚朴酚含量。
1.3综合评分计算方法的选择
1.3.1 AHP法确定综合评分权重系数
根据厚朴酚漱口水成型工艺中各指标的考察结果,将漱口水感官评价和厚朴酚浓度作为权重指标予以量化,即将4项指标分为4个层次,其优先顺序为厚朴酚浓度>外观>口感>气味,判断矩阵评分表见表3。经计算分析确定厚朴酚浓度、外观、口感、气味权重系数分别为38.35%、29.67%、17.21%、14.77%。一致性比列因子(CR)=0.005<0.10,即指标优先比较判断矩阵具有一致性,求得的权重系数有效。
表3判断矩阵评分表
1.3.2 CRITIC法确定综合评分权重系数
CRIRIC法是一种能客观反映厚朴酚漱口水成型工艺指标权重的计算方法。采用CRITIC法确定厚朴酚漱口水成型工艺各指标间的权重,将表12中的数据进行标准化处理[指标成分=(实测值-最小值)/(最大值-最小值)],根据SPSS20.0软件处理数据得相关系数矩阵,再由Cj、Wj公式得厚朴酚浓度、外观、口感、气味权重系数分别为23.31%、19.03%、29.23%、28.44%。
Cj表示第j个指标所包含的信息量、rij表示指标j之间的相关系数,Wj表示j个指标的客观权重,δj为标准化后列向量的标准差。
1.3.3AHP-CRITIC混合加权法确定综合评分权重系数
AHP法主观评价了漱口水成型工艺中各指标的权重系数,体现了漱口水中各成分的添加量对厚朴酚漱口水成型工艺贡献的主次顺序。CRITIC法客观评价了漱口水成型工艺中指标的权重系数,同时考虑了漱口水成型工艺中各数据的变异性和各指标间的冲突性对权重的影响,使得权重更加客观。将两种方法结合计算综合权重,即ω复合ij=ωAHPωCRITIC/∑ωAHPωCRITIC,AHP-CRITIC法计算得厚朴酚浓度、外观、口感、气味权重系数分别为37.54%、23.71%、21.12%、17.64%。
1.3.4三种评分结果比较及综合评分公式确立
选用上述三种评分系数分别对厚朴酚漱口水正交试验结果进行综合评分,三种方法的得分见表4。
关于三种加权得分系数的相关性,通过相关系数分析,AHP法与AHP-CRITIC法的相关系数为0.999,CRITIC法与AHP-CRITIC法的相关系数为0.974,AHP法与CRITIC法的相关系数为0.963,三者相关性显著(P<0.05)。关于权重系数的相关性,AHP法与CRITIC法权相关系数接近0,相关性不显著(P=0.249),说明两种方法所反映的信息不重叠,AHP-CRITIC法从主、客观两个方面考虑,所体现的信息更具有全面性、科学性。因此,本实验采用AHP-CRITIC法计算漱口水工艺的综合评分,综合评分公式如下。
综合评分=[(厚朴酚浓度/厚朴酚浓度max)×0.3754+(外观/外观max)×0.2371+(口感/口感max)×0.2112+(气味/气味max)×0.1764]×100
表4三种赋权法权重结合正交试验综合结果
2、实验结果
厚朴酚漱口水L9(34)正交试验结果见表5,方差分析结果见表6。
根据表5中极差的大小,各因素对漱口水成型工艺影响程度为PEG-400>甘油>薄荷水>β-葡聚糖。根据表13的方差分析,PEG-400因素对试验结果具有显著性影响(P<0.05),甘油、β-葡聚糖、薄荷水因素的影响不显著(P>0.05)。由于β-葡聚糖能够提高机体的免疫力、改善消化道菌群,还具有丰富口感的作用,因此结合β-葡聚糖的常用用量情况,漱口水中加入5mgβ-葡聚糖为更优选的方案;同时,考虑到薄荷水具有提神醒脑、抗菌消炎、止痛、促进消化、增长食欲等功效,所以在最终处方中加重比例,将薄荷水用量调整为20mL。再结合表5中的综合评分,最终确认厚朴酚的漱口水处方优选组成为:厚朴酚(5mg)、PEG400(20ml)、天然甘油(20ml)、β-葡聚糖(5mg)、薄荷水(20ml),加纯水至100ml(实施例1)。
表5正交试验设计与结果
表6方差分析
为验证正交试验结果的准确性,确保新型厚朴酚漱口水成型工艺的合理性与可靠性,按正交试验选出的漱口水最佳工艺处方组成为:厚朴酚(5mg)、PEG400(20ml)、天然甘油(20ml)、β-葡聚糖(5mg)、薄荷水(20ml),加纯水至100ml,进行3次重复性验证实验。验证结果(表7)表明,厚朴酚漱口水各指标的相对标准偏差均在2%以内,表明厚朴酚漱口水最佳成型工艺稳定,可用于进一步研究。
表7工艺验证结果
结合前期的文献分析:厚朴酚作用于口腔多种细菌的抑菌浓度为15.7-31.3ug/ml,杀菌浓度在62.5ug/ml-125ug/ml。本发明实施例厚朴酚漱口水最佳工艺中厚朴酚的浓度为46ug/ml,达到抑菌浓度。
综上,本发明提供了一种品以厚朴酚为主要成分制备的抑菌漱口水,性状稳定,成分简单,制备过程工艺简单,周期短,易于生产,市场竞争力强,应用前景广阔。
Claims (10)
1.一种厚朴酚漱口水,其特征在于,每100mL漱口水包括如下原辅料制成:
厚朴酚5mg,聚乙二醇400 10~20mL,甘油5~20mL,薄荷水10~40mL。
2.如权利要求1所述的厚朴酚漱口水,其特征在于,每100mL漱口水包括如下原辅料制成:
厚朴酚5mg,聚乙二醇400 20mL,甘油10~20mL,薄荷水10~20mL;
优选为:厚朴酚5mg,聚乙二醇400 20mL,甘油20mL,薄荷水20mL。
3.如权利要求1或2所述的厚朴酚漱口水,其特征在于,所述薄荷水是薄荷油的饱和水溶液,所述甘油是天然甘油。
4.如权利要求1或2所述的厚朴酚漱口水,其特征在于,还包括β-葡聚糖。
5.如权利要求4所述的厚朴酚漱口水,其特征在于,每100mL漱口水中所述β-葡聚糖的用量不超过10mg;优选的,所述β-葡聚糖的用量为5mg。
6.如权利要求5所述的厚朴酚漱口水,其特征在于,每100mL漱口水由如下原辅料制成:
厚朴酚5mg,聚乙二醇400 20mL,甘油10~20mL,薄荷水10~20mL,β-葡聚糖5~10mg,余量为水;
优选为:厚朴酚5mg,聚乙二醇400 20mL,甘油20mL,薄荷水20mL,β-葡聚糖5mg,余量为水。
7.如权利要求1、2、5或6所述的厚朴酚漱口水,其特征在于,它是将所述原辅料混匀后超声,静置,过滤,灭菌制得。
8.权利要求1~7任一项所述的漱口水的制备方法,其特征在于,包括如下步骤:
(1)称取厚朴酚,依次加入除水以外的辅料,每次加入辅料后均混匀,最后加水定容;
(2)超声,静置,过滤。
9.如权利要求8所述的制备方法,其特征在于,步骤
(2)所述超声时间为10~20min,所述静置时间为2~4h;优选地,所述超声时间为15min,所述静置时间为3h。
10.如权利要求8所述的制备方法,其特征在于,还包括灌装、灭菌步骤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210862023.8A CN114983879B (zh) | 2022-07-20 | 2022-07-20 | 一种厚朴酚漱口水及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210862023.8A CN114983879B (zh) | 2022-07-20 | 2022-07-20 | 一种厚朴酚漱口水及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114983879A true CN114983879A (zh) | 2022-09-02 |
CN114983879B CN114983879B (zh) | 2023-12-01 |
Family
ID=83021544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210862023.8A Active CN114983879B (zh) | 2022-07-20 | 2022-07-20 | 一种厚朴酚漱口水及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114983879B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2143037A1 (en) * | 1994-05-02 | 1995-11-03 | Atma Chaudhari | Alcohol free mouthwash |
CN101627965A (zh) * | 2009-07-21 | 2010-01-20 | 清华大学 | 一种多功能纯天然漱口水及其制备方法 |
WO2013081627A1 (en) * | 2011-12-02 | 2013-06-06 | Colgate-Palmolive Company | Oral care compositions comprising n-butyl magnolol and isobutyl magnolol |
CN106924120A (zh) * | 2017-04-25 | 2017-07-07 | 上海中翊日化有限公司 | 一种抗菌、清新口气的口腔护理物 |
CN108785161A (zh) * | 2018-07-02 | 2018-11-13 | 亿利耐雀生物科技有限公司 | 一种含甘草黄酮的抑菌漱口水及其制备方法 |
WO2022088724A1 (zh) * | 2020-10-28 | 2022-05-05 | 南京中科游子生物技术研究院有限公司 | 绿茶活性物质漱口水组合物及其制备方法 |
-
2022
- 2022-07-20 CN CN202210862023.8A patent/CN114983879B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2143037A1 (en) * | 1994-05-02 | 1995-11-03 | Atma Chaudhari | Alcohol free mouthwash |
CN101627965A (zh) * | 2009-07-21 | 2010-01-20 | 清华大学 | 一种多功能纯天然漱口水及其制备方法 |
WO2013081627A1 (en) * | 2011-12-02 | 2013-06-06 | Colgate-Palmolive Company | Oral care compositions comprising n-butyl magnolol and isobutyl magnolol |
CN106924120A (zh) * | 2017-04-25 | 2017-07-07 | 上海中翊日化有限公司 | 一种抗菌、清新口气的口腔护理物 |
CN108785161A (zh) * | 2018-07-02 | 2018-11-13 | 亿利耐雀生物科技有限公司 | 一种含甘草黄酮的抑菌漱口水及其制备方法 |
WO2022088724A1 (zh) * | 2020-10-28 | 2022-05-05 | 南京中科游子生物技术研究院有限公司 | 绿茶活性物质漱口水组合物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
陶丽: "超高效液相色谱法检测牙膏和漱口水中厚朴提取物的含量", 《口腔护理用品工业》 * |
Also Published As
Publication number | Publication date |
---|---|
CN114983879B (zh) | 2023-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hosadurga et al. | Effectiveness of two different herbal toothpaste formulations in the reduction of plaque and gingival inflammation in patients with established gingivitis–A randomized controlled trial | |
TWI355945B (zh) | ||
Subramaniam et al. | Effect of pomegranate and aloe vera extract on streptococcus mutans: An: in vitro: study | |
FR3046541A1 (fr) | Principe actif obtenu a partir d'ophiopogon japonicus pour le traitement de la dermatite atopique | |
CN112999131A (zh) | 一种适用于压力肌肤的抗皱修复组合物及其精华乳产品 | |
JP2008088075A (ja) | プロフィラグリン/フィラグリン産生促進剤、表皮角化細胞増殖促進剤、表皮/角層正常化用皮膚外用剤、プロフィラグリン及び/又はフィラグリン産生促進方法、及び表皮角化細胞増殖促進方法 | |
CN102266320B (zh) | 橙皮素的新用途 | |
CN107028784A (zh) | 一种清新口气的口腔护理用品及其制备方法 | |
CN111888308B (zh) | 一种预防口腔溃疡和加速口腔粘膜修复的牙膏及工艺 | |
CN103637961A (zh) | 一种中药润肤乳液 | |
CN113244131A (zh) | 一种清凉清新的口香组合物和口香牙膏及其制备方法 | |
EP2763652A2 (fr) | Utilisation de glucanes obtenus a partir de prunus persica comme agent cosmetique anti-age | |
CN114983879A (zh) | 一种厚朴酚漱口水及其制备方法 | |
AU2011384377B2 (en) | Heatiness and salivary secretory immunoglobulin | |
ACHMAD et al. | The Use of Children's Herbal Mouthwash in Pediatric Dentistry: A Systematic Review. | |
CN108652999A (zh) | 一种儿童牙膏及其制备方法 | |
CN116731785A (zh) | 一种含有青蒿挥发油的乳液及其应用 | |
CN107320401A (zh) | 一种预防龋齿的漱口水及其制备方法 | |
CN113925907A (zh) | 一种抑菌抗炎、抗过敏的组合物及其制备方法和用途 | |
CN107496318A (zh) | 一种含美洲大蠊提取物的脱敏牙膏 | |
US20080069908A1 (en) | Compositions for safe and effective regression of dermal vessel tortuosity in psoriatic lesions | |
WO2021235924A1 (en) | Method and compositions for improving scalp health | |
KR102515366B1 (ko) | 구강 건조 테스터기 | |
CN114028270B (zh) | 一种青蒿精油-毛胶薯蓣多糖微胶囊及其在口腔护理领域的应用 | |
CN112807343B (zh) | 一种口腔菌群多态性调节剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |